U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
Нeparin (or Unfractionated heparin ) is an anticoagulant indicated for both the prevention and treatment of thrombotic events such as deep vein thrombosis (DVT) and pulmonary embolism (PE) as well as atrial fibrillation (AF). Heparin can also be used to prevent excess coagulation during procedures such as cardiac surgery, extracorporeal circulation or dialysis, including continuous renal replacement therapy. Heparin administration can be by intravenous (or subcutaneous route. Intravenous heparin is continuously administered for therapeutic anticoagulation, while intermittent subcutaneous administration is used to prevent thromboembolism. Once administered, heparin binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin (factor IIa) and factor Xa. The heparin-ATIII complex can also inactivate factors IX, XI, XII, and plasmin, but the antithrombotic effect of heparin is well correlated to the inhibition of factor Xa. Typical adverse effects from heparin use include bleeding, thrombocytopenia, injection site reactions, and other adverse effects only seen with chronic heparin administration. Bleeding is a major complication associated with heparin use. Patients should undergo monitoring for new bleeding that may present in the urine or stool. Bleeding may also present as bruising, petechial rash and nosebleeds.

CNS Activity

Curator's Comment: The possibility of heparin penetration into brain cells was shown. The penetration occurred apparently in the form of heparin complexes with thromboplastin.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
281.0 nM [Kd]
607.0 nM [Kd]
106.0 nM [Kd]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
HEPARIN SODIUM

Approved Use

Prophylaxis and treatment of venous thrombosis and pulmonary embolism; Prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdominothoracic surgery or who, for other reasons, are at risk of developing thromboembolic disease; Atrial fibrillation with embolization; Treatment of acute and chronic consumptive coagulopathies (disseminated intravascular coagulation); Prevention of clotting in arterial and cardiac surgery; Prophylaxis and treatment of peripheral arterial embolism. Anticoagulant use in blood transfusions, extracorporeal circulation, and dialysis procedures.

Launch Date

1972
Primary
HEPARIN SODIUM

Approved Use

Prophylaxis and treatment of venous thrombosis and pulmonary embolism; Prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdominothoracic surgery or who, for other reasons, are at risk of developing thromboembolic disease; Atrial fibrillation with embolization; Treatment of acute and chronic consumptive coagulopathies (disseminated intravascular coagulation); Prevention of clotting in arterial and cardiac surgery; Prophylaxis and treatment of peripheral arterial embolism. Anticoagulant use in blood transfusions, extracorporeal circulation, and dialysis procedures.

Launch Date

1972
Primary
HEPARIN SODIUM

Approved Use

Prophylaxis and treatment of venous thrombosis and pulmonary embolism; Prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdominothoracic surgery or who, for other reasons, are at risk of developing thromboembolic disease; Atrial fibrillation with embolization; Treatment of acute and chronic consumptive coagulopathies (disseminated intravascular coagulation); Prevention of clotting in arterial and cardiac surgery; Prophylaxis and treatment of peripheral arterial embolism. Anticoagulant use in blood transfusions, extracorporeal circulation, and dialysis procedures.

Launch Date

1972
PubMed

PubMed

TitleDatePubMed
Heparin.
2024 Jan

Sample Use Guides

Deep Subcutaneous (Intrafat) Injection: Initial -- 5,000 units by intravenous injection, followed by 10,000 units to 20,000 units of a concentrated solution Every 8 hours: 8,000 units to 10,000 units of a concentrated solution Intermittent Intravenous Injection: Initial: 10,000 units, either undiluted or in 50 mL to 100 mL of 0.9% Sodium Chloride Injection, USP by intravenous injection Every 4 to 6 hours: 5,000 units to 10,000 units, either undiluted or in 50 mL to 100 mL of 0.9% Sodium Chloride Injection, USP
Route of Administration: Other
Name Type Language
HEPARIN CALCIUM
JAN   ORANGE BOOK   USP   VANDF   WHO-DD   WHO-IP  
Common Name English
HEPARIN CALCIUM [JAN]
Common Name English
HEPARIN CALCIUM [VANDF]
Common Name English
HEPARIN CALCIUM SALT [MI]
Common Name English
Heparin calcium [WHO-DD]
Common Name English
HEPARIN CALCIUM [ORANGE BOOK]
Common Name English
HEPARIN CALCIUM [WHO-IP]
Common Name English
HEPARINUM CALCICUM [WHO-IP LATIN]
Common Name English
HEPARIN CALCIUM [USP IMPURITY]
Common Name English
HEPARIN CALCIUM [EP MONOGRAPH]
Common Name English
ECASOLV
Brand Name English
CALCIPARINE
Brand Name English
Classification Tree Code System Code
NCI_THESAURUS C263
Created by admin on Sat Dec 16 13:13:30 GMT 2023 , Edited by admin on Sat Dec 16 13:13:30 GMT 2023
Code System Code Type Description
WHO INTERNATIONAL PHARMACOPEIA
HEPARIN CALCIUM
Created by admin on Sat Dec 16 13:13:30 GMT 2023 , Edited by admin on Sat Dec 16 13:13:30 GMT 2023
PRIMARY Description: A white or almost white powder. Solubility: Freely soluble in water.Category: Anticoagulant. Storage: Heparin calcium should be kept in a tightly closed container. Labelling: The designation Heparin calcium for parenteral use indicates that the substance complies with the additional requirements and may be used for parenteral administration. The label should also state the name and quantity of any added substances, and the source of the material (lung or mucosal). Expiry date. Additional information: Heparin calcium is moderately hygroscopic.Definition: Heparin calcium is a preparation containing the calcium salt of a sulfated glucosaminoglycan present in mammalian tissues. It has the characteristic property of delaying the clotting of fresh blood.Heparin calcium intended for the manufacture of a parenteral dosage form contains not less than 150 IU per mg, and Heparin calcium not intended for use in the manufacture of a parenteral dosage form contains not less than 120 IU per mg, both calculated with reference to the dried substance.
SMS_ID
100000092067
Created by admin on Sat Dec 16 13:13:30 GMT 2023 , Edited by admin on Sat Dec 16 13:13:30 GMT 2023
PRIMARY
CAS
37270-89-6
Created by admin on Sat Dec 16 13:13:30 GMT 2023 , Edited by admin on Sat Dec 16 13:13:30 GMT 2023
GENERIC (FAMILY)
ChEMBL
CHEMBL1201513
Created by admin on Sat Dec 16 13:13:30 GMT 2023 , Edited by admin on Sat Dec 16 13:13:30 GMT 2023
PRIMARY
FDA UNII
M4F288ZCTR
Created by admin on Sat Dec 16 13:13:30 GMT 2023 , Edited by admin on Sat Dec 16 13:13:30 GMT 2023
PRIMARY
EVMPD
SUB02476MIG
Created by admin on Sat Dec 16 13:13:30 GMT 2023 , Edited by admin on Sat Dec 16 13:13:30 GMT 2023
PRIMARY
NCI_THESAURUS
C1034
Created by admin on Sat Dec 16 13:13:30 GMT 2023 , Edited by admin on Sat Dec 16 13:13:30 GMT 2023
PRIMARY
RXCUI
20044
Created by admin on Sat Dec 16 13:13:30 GMT 2023 , Edited by admin on Sat Dec 16 13:13:30 GMT 2023
PRIMARY RxNorm
DRUG BANK
DBSALT001434
Created by admin on Sat Dec 16 13:13:30 GMT 2023 , Edited by admin on Sat Dec 16 13:13:30 GMT 2023
PRIMARY
MERCK INDEX
m5958
Created by admin on Sat Dec 16 13:13:30 GMT 2023 , Edited by admin on Sat Dec 16 13:13:30 GMT 2023
PRIMARY Merck Index
Display Structure of HEPARIN CALCIUM